Capricor Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update
09 août 2018 16h00 HE
|
Capricor Therapeutics, Inc.
To Host Conference Call and Webcast Today at 4:30 p.m. ET LOS ANGELES, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology...
Capricor Therapeutics to Present Second Quarter Financial Results and Corporate Update on August 9
02 août 2018 16h00 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, Aug. 02, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for...
Capricor and USAISR Announce Collaboration to Investigate Exosome Platform to Treat Injured Troops
17 juil. 2018 07h00 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, July 17, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR) today announced it has entered into an agreement with the U.S. Army Institute of Surgical Research (USAISR) to...
Capricor Therapeutics and PPMD to Host Webinar for Duchenne Muscular Dystrophy Community on July 18
13 juil. 2018 09h00 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, July 13, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR) and Parent Project Muscular Dystrophy (PPMD) will host a webinar at 1 p.m. ET on July 18 to provide information...
Capricor Therapeutics to Present at PPMD Annual Conference
28 juin 2018 07h00 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, June 28, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics’ (NASDAQ:CAPR) chief medical officer, Deborah Ascheim, M.D., will present a corporate overview at the Parents Project Muscular...
Capricor Therapeutics to Present at the 2018 BIO International Convention in Boston
29 mai 2018 07h00 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, May 29, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing biological therapies for Duchenne muscular dystrophy and other rare disorders,...
Capricor Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update
10 mai 2018 16h00 HE
|
Capricor Therapeutics, Inc.
HOPE-2 Clinical Trial is Currently Enrolling Patients Conference Call and Webcast Today at 4:30 p.m. ET LOS ANGELES, May 10, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a...
Capricor Therapeutics to Present First Quarter 2018 Financial Results and Corporate Update on May 10
04 mai 2018 08h00 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, May 04, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for...
Capricor to Present on Exosomes at the Plenary Session of the International Society for Cellular Therapy in Montreal
03 mai 2018 07h00 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, May 03, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR) today announced that Linda Marbán, Ph.D., Capricor president and CEO, will provide a presentation on exosomes at...
Capricor Announces Initiation of HOPE-2 Clinical Trial of CAP-1002 for Duchenne Muscular Dystrophy
30 avr. 2018 07h00 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, April 30, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ:CAPR) today announced it has initiated the HOPE-2 clinical trial at UC Davis Medical Center. The trial will test...